Jonathan Rubin Sells 927 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Stock

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) SVP Jonathan Rubin sold 927 shares of the company’s stock in a transaction dated Friday, February 21st. The shares were sold at an average price of $39.15, for a total transaction of $36,292.05. Following the transaction, the senior vice president now owns 7,853 shares in the company, valued at approximately $307,444.95. The trade was a 10.56 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Supernus Pharmaceuticals Price Performance

Shares of NASDAQ:SUPN opened at $32.81 on Wednesday. The company has a market capitalization of $1.81 billion, a price-to-earnings ratio of 30.66 and a beta of 0.90. The firm’s 50 day simple moving average is $37.34 and its 200 day simple moving average is $35.39. Supernus Pharmaceuticals, Inc. has a fifty-two week low of $25.53 and a fifty-two week high of $40.28.

Institutional Trading of Supernus Pharmaceuticals

A number of hedge funds have recently modified their holdings of the company. Vanguard Group Inc. raised its position in shares of Supernus Pharmaceuticals by 0.4% in the 4th quarter. Vanguard Group Inc. now owns 6,150,759 shares of the specialty pharmaceutical company’s stock valued at $222,411,000 after acquiring an additional 22,852 shares during the period. Stephens Investment Management Group LLC increased its stake in Supernus Pharmaceuticals by 1.8% during the 3rd quarter. Stephens Investment Management Group LLC now owns 1,932,209 shares of the specialty pharmaceutical company’s stock worth $60,246,000 after purchasing an additional 33,710 shares in the last quarter. Pacer Advisors Inc. increased its stake in Supernus Pharmaceuticals by 29.9% during the 3rd quarter. Pacer Advisors Inc. now owns 1,752,882 shares of the specialty pharmaceutical company’s stock worth $54,655,000 after purchasing an additional 403,028 shares in the last quarter. Geode Capital Management LLC increased its stake in Supernus Pharmaceuticals by 1.9% during the 4th quarter. Geode Capital Management LLC now owns 1,510,568 shares of the specialty pharmaceutical company’s stock worth $54,633,000 after purchasing an additional 28,517 shares in the last quarter. Finally, American Century Companies Inc. increased its stake in Supernus Pharmaceuticals by 9.2% during the 4th quarter. American Century Companies Inc. now owns 1,140,705 shares of the specialty pharmaceutical company’s stock worth $41,248,000 after purchasing an additional 95,777 shares in the last quarter.

Wall Street Analysts Forecast Growth

Separately, Cantor Fitzgerald downgraded shares of Supernus Pharmaceuticals from an “overweight” rating to a “neutral” rating and cut their target price for the company from $57.00 to $36.00 in a research report on Wednesday, February 19th.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.